Contralateral Prophylactic Mastectomy in Breast Cancer: What to Discuss with Patients
Overview
Pharmacology
Authors
Affiliations
: The contralateral prophylactic mastectomy (CPM) rate in the U.S. has been steadily increasing. This is of particular concern because many women who undergo this procedure are candidates for breast-conserving surgery.: CPM's medical benefit is related to the risk of contralateral cancer development and whether CPM provides a survival benefit. Contralateral cancer rates have decreased, and CPM does not provide a survival benefit. Other potential benefits of the procedure may be improved quality of life; these data are reviewed. Research efforts have been undertaken to better understand the decision-making process of patients who consider, and ultimately undergo, this procedure.: Decisional traits, personal values, the desire for peace of mind, and the desire to obtain breast symmetry are important factors that drive a woman's decision to undergo CPM. Additionally, many patients lack the knowledge on how different types of breast surgery impact outcomes. To improve the shared decision-making process, a stepwise approach to address possible misconceptions, and clarify the real risks/benefits of this procedure should be utilized. A clear recommendation (for/against) should be made for every patient with newly diagnosed breast cancer who considers CPM. Communication tools to assist patients and surgeons in this process are sorely needed.
Vingan P, Serafin J, Boe L, Zhang K, Kim M, Sarraf L Ann Surg Oncol. 2024; 31(6):3684-3693.
PMID: 38388930 PMC: 11267583. DOI: 10.1245/s10434-024-15094-2.
Singh P, Agnese D, Amin M, Barrio A, van den Bruele A, Burke E Ann Surg Oncol. 2024; 31(4):2212-2223.
PMID: 38261126 DOI: 10.1245/s10434-024-14893-x.
Myers S, Tadros A, Sevilimedu V, Nelson J, Le T, Garcia P Ann Surg Oncol. 2023; 30(12):7116-7123.
PMID: 37581851 PMC: 10996069. DOI: 10.1245/s10434-023-14086-y.
Contralateral Prophylactic Mastectomy Decision-Making: The Partners' Perspective.
Nash A, Bloom D, Chapman B, Wheeler S, McGuire K, Lee C Ann Surg Oncol. 2023; 30(10):6268-6274.
PMID: 37573282 DOI: 10.1245/s10434-023-14022-0.
Bharmjeet , Das A Cancer Rep (Hoboken). 2023; 6 Suppl 1:e1807.
PMID: 36971312 PMC: 10440846. DOI: 10.1002/cnr2.1807.